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Disorders of mineral metabolism develop early in chronic
kidney disease, but it appears that Blacks with stage-5
disease have more severe secondary hyperparathyroidism
than other races. We measured levels of parathyroid
hormone, calcium, phosphorus, 25-hydroxyvitamin D (25D)
and 1,25-dihydroxyvitamin D (1,25D) in 227 Black and 1633
non-Black participants in the SEEK study, a multi-center
cohort of patients with early chronic kidney disease. Overall,
Blacks had similar 1,25D levels compared with non-Blacks,
but significantly lower levels of 25D with higher levels of
calcium, phosphorus, and parathyroid hormone, and were
significantly more likely to have hyperphosphatemia than
non-Blacks. In multivariable analyses adjusted for age,
gender, estimated glomerular filtration rate, body mass
index, and diabetes, Blacks had significantly lower 25D
and higher parathyroid hormone levels than non-Blacks,
with the latter parameter remaining significant after
further adjustment for calcium, phosphorus, 25D, and
1,25D. The association between Black race and secondary
hyperparathyroidism, independent of known risk factors,
suggests that novel mechanisms contribute to secondary
hyperparathyroidism in Blacks with chronic kidney disease.
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Disordered mineral metabolism, secondary hyperpara-
thyroidism (sHPT), and deficiencies of vitamin D are
common complications of chronic kidney disease (CKD).1,2
While their contributions to the development of renal
osteodystrophy are well known,3 recent evidence has linked
these factors to cardiovascular disease, including non-
atherosclerotic vascular calcification, excessive activation of
the renin–angiotensin system, hypertension, left ventricular
hypertrophy, and death.4–10 Indeed, large observational
studies suggest that abnormalities of parathyroid hormone
(PTH), calcium, phosphorus, 25-hydroxyvitamin D (25D),
and 1,25-dihydroxyvitamin D (1,25D) are associated with
mortality on dialysis, and that management strategies to treat
these disorders may improve survival.11–14 On the basis of
these encouraging results, renewed emphasis has shifted to
the screening and treatment of these abnormalities early in
the course of CKD when they first develop and may be most
amenable to therapy.
In the general population, Blacks demonstrate increased
rates of 25D deficiency and increased PTH levels compared
with non-Blacks.15–17 These differences are magnified on
dialysis when Blacks manifest more severe sHPT and 25D
deficiency than Caucasians.14,18,19 However, few population-
based studies have examined racial differences in the preva-
lence and severity of mineral metabolism disorders in
pre-dialysis CKD.20 This is especially noteworthy since Blacks
bear a disproportionately higher burden of CKD,21–23
yet current Kidney Disease Outcomes Quality Initiative
(K/DOQI) guidelines for the management of mineral
metabolism in CKD primarily considered studies that did
not specifically account for potential racial differences in
abnormalities of mineral metabolism.24–28 We examined the
Study for Early Evaluation of Kidney Disease (SEEK) cohort
to test the hypotheses that sHPT, hypocalcemia, hyper-
phosphatemia, and deficiencies of 25D and 1,25D are more
common and more severe among Blacks compared with non-
Blacks, and that Blacks manifest these abnormalities earlier
along the spectrum of pre-dialysis CKD.
RESULTS
Patient characteristics
A total of 1860 subjects were analyzed, of whom 12% (227)
were Black, which is similar to their representation in the US
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population.29 Demographic and clinical data by race are
presented in Table 1. Compared with non-Blacks, Blacks were
younger, more likely to be female, had lower estimated
glomerular filtration rate (eGFR), and higher body mass
index and systolic blood pressure. Blacks were more likely
to have a history of diabetes mellitus and hypertension
than non-Blacks, but less likely to have a history of coronary
artery disease. Blacks were more likely to be treated with
angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, calcium channel blockers, and diuretics
than non-Blacks, but were less likely to be treated with
calcium supplements. Among patients with a history of
coronary artery disease, Blacks were as likely as non-Blacks to
be treated with angiotensin-converting enzyme inhibitors
(44 vs 38%, P¼ 0.4), aspirin (76 vs 70%, P¼ 0.3), b-blockers
(71 vs 60%, P¼ 0.08), and 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (65 vs 73%, P¼ 0.2),
suggesting that there were minimal differences in access to
quality medical care according to race.
Mineral metabolites by race and CKD stage
Table 2 shows the levels of PTH, calcium, phosphorus, bone-
specific alkaline phosphatase, 25D, and 1,25D in the overall
population by race. Whereas Blacks had similar levels of
1,25D compared with non-Blacks, they had significantly
higher levels of PTH, calcium, phosphorus, and alkaline
phosphatase, and lower levels of 25D. On the basis of clinically
accepted cut-off points, Blacks were significantly more likely
to have sHPT (PTH465 pg ml1), hyperphosphatemia
(44.6 mg per 100 ml), 25D deficiency (o30 ng ml1), and
severe 25D deficiency (o10 ng ml1) compared with non-
Blacks (Table 2).
Racial differences in the levels of PTH, calcium, phos-
phorus, 25D, and 1,25D by CKD stage and the stage-specific
prevalence of values outside the normal range are presented in
Table 3 and Figure 1. There were no significant racial
differences in median 1,25D levels across the spectrum of
CKD. Blacks had a similar prevalence of 1,25D deficiency as
non-Blacks in each stage of CKD except in the most advanced
stage (eGFRo30 ml min1 1.73 m2), where Blacks had a
significantly lower prevalence of 1,25D deficiency compared
with non-Blacks (Figure 1a). In contrast, Blacks had signi-
ficantly lower 25D and higher PTH levels, and a significantly
higher prevalence of both 25D deficiency and sHPT than non-
Blacks in all stages of CKD (Figure 1b and c). Importantly,
median levels of PTH first exceeded 65 pg ml1 at an eGFR
o30 ml min1 1.73 m2 in non-Blacks, whereas among Blacks,
significant sHPT was present in 460% of patients with an
eGFR of 45–60 ml min1 1.73 m2. Blacks had higher calcium
and phosphorus levels than non-Blacks in each stage of CKD,
although differences did not reach statistical significance in
every stage. Similarly, Blacks had a higher prevalence of
hyperphosphatemia in each stage of CKD (Figure 1d),
although differences were only statistically significant in the
earliest stage of CKD (eGFR460 ml min1 1.73 m2). There
were no statistically significant differences in the prevalence of
hypocalcemia in Blacks compared with non-Blacks (Figure 1e).
Multivariable analyses
In multivariable linear regression models adjusted for age,
gender, diabetes, body mass index, and eGFR, Black, race was
independently associated with increased log PTH (b¼ 0.49,
Table 1 | Description of subjects by race
Black Non-Black
Variable n=227 n=1633 P
Age 67±11 71±11 o0.01
Female (%) 61 51 o0.01
Body mass index (kg m2) 33±8 31±7 o0.01
SBP (mm Hg) 136±20 130±17 0.02
EGFR (ml min 1.73m2) 45±20 48±18 0.04
Comorbidities (%)
Diabetes 59 46 o0.01
CAD 31 39 0.01
CHF 24 18 NS
CVA 6 10 NS
HTN 97 86 o0.01
PVD 17 17 NS
Smoking 23 19 NS
Medications (%)
ACE inhibitor 48 37 o0.01
ARB 43 33 o0.01
CCB 51 34 o0.01
Diuretics 75 62 o0.01
b-Blockers 44 44 NS
ASA 55 55 NS
Calcium supplements 19 27 0.02
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; ASA,
aspirin; CAD, coronary artery disease; CCB, calcium channel blocker; CHF, congestive
heart failure; CVA, cerebral vascular accident; eGFR, estimated glomerular filtration
rate (by the MDRD equation); HTN, hypertension; NS, not significant; PVD, peripheral
vascular disease; SBP, systolic blood pressure.
Results are reported as mean±s.d. or proportions.
Table 2 | Laboratory variables in the overall population by
race
Black Non-Black
Variable n=227 n=1633 P
1,25D (pg ml1) 28 (18–39) 29 (19–40) NS
%o30 pg ml1 49 50 NS
25D (ng ml1) 22±11 30±12 o0.01
%o30 ng ml1 83 60 o0.01
%o10 ng ml1 11 3 o0.01
PTH (pg ml1) 92 (55–171) 53 (34–84) o0.01
%465 pg ml1 65 38 o0.01
Albumin (g per 100 ml) 4.2±0.3 4.3±0.4 o0.01
Bone alkaline phosphatase (U l1) 25 (19–34) 21 (17–27) o0.01
Calcium (mg per 100 ml) 9.2±0.6 9.1±0.4 o0.01
%o8.5 mg per 100 ml 5 4 NS
Phosphorus (mg per 100 ml) 3.9±0.7 3.7±0.7 o0.01
%44.6 mg per 100 ml 15 8 o0.01
25D, 25-hydroxyvitamin D; 1,25D, 1,25-dihydroxyvitamin D; NS, not significant; PTH,
parathyroid hormone.
Results are reported as mean±s.d., median (interquartile range), or proportions.
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Po0.01), calcium (b¼ 0.1, Po0.01), phosphorus (b¼ 0.11,
P¼ 0.04), and log alkaline phosphatase (b¼ 0.12, Po0.01),
and decreased levels of 25D (b¼6.2, Po0.01). Thus,
whereas there were no significant racial differences in
multivariable-adjusted 1,25D levels, the Black race was inde-
pendently associated with 40% higher PTH, 2% higher
calcium, 3% higher phosphorus, 14% higher alkaline phos-
phatase, and 21% lower 25D levels. When further adjusted
for 25D, 1,25D, calcium, and phosphorus levels, the Black
race remained independently associated with increased log
PTH (b¼ 0.44, Po0.01), but the association between race
and log alkaline phosphatase was completely attenuated
when adjusted for log PTH (b¼ 0.02, P¼ 0.7). In addition,
when further adjusted for 25D levels, an association between
Black race and increased log 1,25D levels became evident
(b¼ 0.16, Po0.01).
In logistic regression models adjusted for age, gender,
diabetes, body mass index, and eGFR, there were no signi-
ficant racial differences in risk of 1,25D deficiency or hypo-
calcemia on the basis of clinical cut-off points defined above.
In contrast, Blacks had a 1.8-fold greater risk of hyper-
phosphatemia (95% confidence interval: 1.01, 3.3, P¼ 0.04),
a 2.9-fold greater risk of sHPT (95% confidence interval: 1.9,
4.4; Po0.01), a 2.7-fold greater risk of 25D deficiency
Table 3 | Laboratory values by race and eGFR
GFR460 GFR 45–59 GFR 30–44 GFRo30
Black Non-Black Black Non-Black Black Non-Black Black Non-Black
n=47 n=385 n=51 n=513 n=82 n=466 n=47 n=269
1,25D (pg ml1) 34 (26–53) 37 (27–52) 32 (25–43) 32 (23–44) 25 (15–36) 25 (16–34) 25 (14–33) 19 (10–28)
25D (ng ml1) 22±9** 32 ±12 23±11** 31±12 21±11** 29±11 21±14* 27±13
PTH (pg ml1) 54 (34–81)** 40 (29–56) 71 (52–116)** 49 (31–69) 107 (63–172)** 61 (40–93) 218 (119–459)** 101 (62–173)
Ca (mg per 100 ml) 9.3±0.4** 9.1±0.4 9.3±0.4** 9.2±0.4 9.2±0.5 9.2±0.5 9.1±0.9 9.0±0.6
P (mg per 100 ml) 3.6±0.7 3.5±0.5 3.7±0.6 3.6±0.5 3.9±0.5** 3.7±0.6 4.4±0.9 4.2±0.9
1,25D, 1,25-dihydroxyvitamin D; 25D, 25-hydroxyvitamin D; Ca, calcium; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; NS, not significant; P,
phosphorus; PTH, parathyroid hormone.
25D, Ca, and P are reported as mean±s.d.; 1,25D and PTH are reported as median (interquartile range). *Po0.05, **Po0.01 for comparison between Black and non-Black.
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Figure 1 | Racial differences in mineral metabolism by stage of CKD. Prevalence of 1,25D deficiency (a), 25D deficiency (b), sHPT
(c), hyperphosphatemia (d), and hypocalcemia (e) by CKD stage and race. Filled bars refer to Blacks and open bars refer to non-Blacks.
The asterisk represents significant (Po0.05) differences between Blacks and non-Blacks.
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(o30 ng ml1, 95% confidence interval: 1.7, 4.5, Po0.01),
and a 4.6-fold greater risk of severe 25D deficiency
(o10 ng ml1, 95% confidence interval: 2.2, 9.6, Po0.01)
than non-Blacks.
DISCUSSION
In this cross-sectional study of 1860 pre-dialysis CKD
patients, Blacks had significantly increased PTH, calcium,
phosphorus, and bone-specific alkaline phosphatase levels;
significantly decreased 25D levels; and a higher prevalence of
sHPT and 25D deficiency overall and in all stages of CKD
compared with non-Blacks. Blacks also developed sHPT and
25D deficiency earlier in the course of CKD (at eGFR of
45–60) compared with non-Blacks (at GFRo30). To our
knowledge, this is the largest study of racial disparities in the
prevalence and severity of disordered mineral metabolism in
pre-dialysis CKD. The results suggest that screening for
disorders of mineral metabolism should be performed earlier
in Blacks with CKD. Furthermore, the observation that Blacks
manifest more severe sHPT independent of age, gender,
diabetes, eGFR, calcium, phosphorus, 25D, and 1,25D
suggests that other pathophysiological mechanisms may play
a role in the early development of sHPT in Blacks with CKD.
Disorders of mineral metabolism are common complica-
tions of CKD that are associated with increased risk of
cardiovascular disease and mortality.4–10,12 Hyperphosphate-
mia, sHPT, 25D, and 1,25D deficiency have all been linked
with increased risk of mortality on dialysis.11–14 Whereas
these associations have been studied in less detail in non-
dialysis populations, increases in serum phosphorus even in
the high normal range have been associated with accelerated
kidney disease progression and increased mortality in
patients with pre-dialysis CKD,30,31 suggesting that even
mildly elevated levels of phosphorus may have deleterious
consequences. Among subjects with normal kidney function,
higher serum phosphorus and PTH levels and lower 25D
levels have been associated with an increased risk of CVD
events, including congestive heart failure, hypertension, and
stroke.32–36 Low 25D levels have also been associated with a
variety of malignancies, autoimmune diseases, and impaired
immune response to tuberculosis infection, especially among
Blacks.37,38 While the pathophysiological mechanisms that
account for these associations must be elucidated, a growing
number of in vitro animal and human studies have linked
elevated serum phosphorus and PTH levels and low 25D and
1,25D levels with left ventricular hypertrophy, impaired
myocardial contractile function, accelerated vascular calcifi-
cation, and atherosclerosis.9,39,40 Altogether, these observa-
tions suggest that disorders of mineral metabolism may be
important and potentially modifiable risk factors for the
abysmal cardiovascular outcomes in patients with CKD.
Recognizing the possibility that abnormal mineral, PTH,
and vitamin D metabolism may represent novel risk factors
for cardiovascular disease in CKD, current K/DOQI clinical
practice guidelines advocate screening for and treating these
abnormalities as early as eGFRo60 ml min1 1.73 m2.24 The
validity of this approach was supported by several studies
that demonstrated a high prevalence of abnormal mineral
metabolism starting in CKD stage 3.1,2,25–28,41 However,
virtually all of the published studies on which the guidelines
were based neither specifically studied the effects of race, nor
did they consistently describe the racial characteristics of
the study populations, and thus generalizing these results
to Black patients may be inappropriate. Indeed, the results
of this and previous studies20 suggest that current screen-
ing algorithms may be inadequate for Black CKD patients.
For example, current guidelines do not recommend measur-
ing PTH or 25D levels until eGFR decreases to
o60 ml min1 1.73 m2 because in previous studies, PTH
levels first rose above the normal range at this level of
eGFR.25,27,42 However, we observed that 43% of Black
patients with eGFRX60 ml min1 1.73 m2 already had
PTH levels 465 pg ml1, and over 80% of these patients
had 25D levels o30 ng ml1. Thus, we propose that routine
screening for sHPT and 25D deficiency may be necessary as
early as CKD stage 2 for Blacks to identify and treat patients
prior to development of more severe disease. In fact, on the
basis of previous studies of healthy populations in which
Blacks also had higher PTH and lower 25D levels than
Caucasians,15–17 and our similar observations in the Black
patients with relatively preserved kidney function
(X60 ml min1 1.73 m2) in this study, more generalized
screening of Blacks even outside of CKD may be warranted.
Although Blacks maintain higher bone mass than Whites
despite their lower 25D levels and increased PTH levels,17
25D deficiency is associated with certain malignancies,
cardiovascular disease, and abnormal immune function.
Randomized trials and cost-effectiveness studies are needed
to examine whether earlier intervention supported by earlier
screening may benefit Blacks, especially in terms of prevent-
ing neoplastic, cardiovascular, autoimmune, and infectious
diseases.
Hypocalcemia, decreased vitamin D levels, and hyper-
phosphatemia are the main physiological stimuli for
increased PTH secretion.3 Blacks are at increased risk of
developing 25D deficiency because increased skin pigmenta-
tion limits cutaneous conversion of 7-dehydrocholesterol to
cholecalciferol, the precursor of 25D. While the higher
prevalence and severity of sHPT in Blacks compared with
non-Blacks was partially related to their high rate of 25D
deficiency, it is interesting to note that the increase in PTH
levels among Blacks was independent of serum calcium,
phosphorus, 25D, and 1,25D levels. This suggests that other
mechanisms may play a role in the development of sHPT in
Blacks. We can speculate several possibilities. For example,
there could be racial differences in the expression or activity
of calcium-sensing receptors in the parathyroid glands.
Activation of calcium-sensing receptors by increased ionized
calcium inhibits PTH secretion,43 and decreased expression
of calcium-sensing receptors is a mechanism of sHPT in
CKD.44 In a study of healthy volunteers, induction of
hypercalcemia suppressed PTH secretion in Black subjects
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less effectively than Caucasian subjects, suggesting that Blacks
may have reduced calcium-sensing capacity.45 Alternatively,
greater skeletal resistance to PTH among Blacks may be an
additional mechanism for their increased PTH.46 However,
we observed significantly higher bone-specific alkaline
phosphatase levels, suggesting increased bone turnover in
Blacks compared with non-Blacks. Furthermore, the finding
that adjustment for PTH attenuated the racial difference
in bone-specific alkaline phosphatase suggests that Blacks
may have higher alkaline phosphatase because of higher
PTH levels, arguing against skeletal resistance to PTH.
Further studies of early CKD patients are needed to dissect
these possibilities.
It is interesting that Blacks had significantly higher serum
phosphorus levels and a higher risk of developing hyper-
phosphatemia than non-Blacks despite their greater PTH
levels. It is possible that greater phosphorus intake among
Blacks led to increased serum levels which stimulated
increased PTH. We could not analyze this possibility because
we did not have data on dietary history. However, several large
population-based studies have documented that US Blacks
have equivalent to slightly lower daily intake of dairy products,
calcium, and phosphorus than non-Blacks,47 and previous
physiological studies have demonstrated that significant
differences in 25D, 1,25D, and PTH levels persist between
Blacks and Whites fed identical standardized diets.17,48 Thus,
increased dietary intake of phosphorus is unlikely to explain
the higher serum phosphorus levels in Blacks compared with
non-Blacks in this study. Alternatively, renal resistance to the
phosphaturic stimulus of PTH or decreased expression, or
resistance to other phosphaturic hormones such as fibroblast
growth factor-23 and klotho, may have contributed.49 In
support of the latter is the observation that Blacks had
significantly higher 1,25D levels than non-Blacks after
accounting for their significantly lower 25D stores. While this
could be attributed to their higher PTH levels,50 it is
interesting to speculate whether lower levels of fibroblast
growth factor-23, a potent inhibitor of 1,25D synthesis,49
might explain the coexistence of higher 1,25D and phosphorus
levels in Blacks compared with non-Blacks that we observed in
this study. We could not measure fibroblast growth factor-23
due to insufficient blood samples; so additional studies are
needed to determine if there are racial differences in fibroblast
growth factor-23 levels in health and in CKD.
We acknowledge several limitations to this study. First, the
cross-sectional design precluded the analyses of longitudinal
changes in mineral metabolism over time, so we could only
draw inferences on the direction of the associations we
observed with caution. Nevertheless, the absolute rates of
abnormal mineral metabolites according to race are clinically
relevant despite this limitation. Second, whereas data on the
use of calcium supplements were collected, data on calcium
prescribed specifically as a phosphate binder were not
available. However, given that the majority of patients had
early CKD and were recruited from primary care practices,
few patients were likely treated with binders. Furthermore,
the results were unchanged when we adjusted for calcium
supplements and when we repeated the analyses after exclud-
ing those who were treated with calcium. Third, although we
were unable to adjust for potential differences in socio-
economic status, all subjects were recruited from outpatient
community health care practices, and Blacks had similar,
if not better, ‘quality of care’ markers than non-Blacks on
the basis of medication utilization patterns overall and in
patients with coronary artery disease. Taken together, this
suggests that disparities in access to quality health care were
unlikely to account for these results. Fourth, because subjects
were classified as either Black or non-Black in the original
SEEK study (for the purpose of the modification of diet
in renal disease (MDRD) eGFR estimation), we were unable
to extend the analyses to other race/ethnicities such as
Asians, Native Americans, and Hispanics. Indeed, by group-
ing members of these minorities together with Caucasians
in the non-Black group, we likely underestimated the true
differences between Blacks and Caucasians, since, for
example, Hispanics are known to have decreased 25D levels
compared with Caucasians.14,51 Finally, although we report
important associations between race and disordered mineral
metabolism, only randomized trials could definitively deter-
mine whether early screening and treatment of these
abnormalities may have a salutary effect on CKD, bone, or
cardiovascular end points.
We conclude that disorders of mineral metabolism, parti-
cularly sHPT and 25D deficiency, are more common, more
severe, and develop earlier in the course of CKD in Blacks
compared with non-Blacks. These findings expand our
current understanding of racial disparities in these disorders,
suggest a need to reevaluate screening algorithms, and most
importantly, highlight the importance of dedicated studies of
Blacks and other minorities to address potential biological
explanations for the marked racial disparities in health care
outcomes related to CKD.
MATERIALS AND METHODS
Study population
The design of the SEEK study has been described in detail
elsewhere.1 Briefly, SEEK is a multi-center, community-based,
observational cohort study designed to evaluate the prevalence of
abnormalities in levels of PTH, calcium, phosphorus, 25D, and
1,25D in patients with CKD. More than 70% of subjects were
recruited from primary care practices that were equally distributed
throughout the US. Subjects were eligible for enrollment if they
had eGFRo60 ml min1 1.73 m2 on the basis of the simplified
Modification of Diet in Renal Disease equation52 calculated from
their most recent serum creatinine recorded in the outpatient
medical record. Exclusion criteria included renal replacement
therapy, a history of primary parathyroid disease, or use of any
prescription-based vitamin D therapy in the 12 months before
screening. Dietary supplementation or multivitamin intake of up to
400 IU per day of vitamin D was not an exclusion criterion.
Clinical data and blood samples were collected after subjects
provided written informed consent. Estimated GFR for the
study was recalculated on the basis of the serum creatinine
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measured in the study samples; hence some subjects had eGFR4
60 ml min1 1.73 m2. To minimize confounding due to differences
in sunlight exposure, all blood samples were obtained at peak
sunlight season from June through September 2004.
Variables of interest
The primary exposure was race, which was ascertained by patient
self-report and categorized as Black or non-Black for the purpose of
estimating GFR; ethnicity was not ascertained. Medical history and
current medications were captured at the baseline visit. Blood was
collected for serum creatinine, PTH, calcium, phosphorus, 25D,
1,25D, bone-specific alkaline phosphatase, and albumin. All assays
were performed at a central laboratory (Quintiles Laboratories Ltd,
NJ, USA) by technicians who were blinded to clinical data. Calcium,
phosphorus, alkaline phosphatase, and creatinine were measured
with a commercial auto-analyzer using standard assays. Total
calcium was corrected for serum albumin levels using the following
equation: corrected calcium¼ total calciumþ 0.8 (4.0albumin).
Serum intact PTH was determined by a chemiluminescence assay
(DPC, Los Angeles, CA, USA); 25D and 1,25D were determined
using radioimmunoassays (Diasorin, Stillwater, MN, USA). On the
basis of current K/DOQI guidelines,24 and for the purpose of
interpretability, 25D deficiency was defined as a level o30 ng ml1,
whereas severe 25D deficiency was defined as a level o10 ng ml1.
sHPT was defined as PTH465 pg ml1, hypocalcemia as o8.5 mg
per 100 ml, and hyperphosphatemia as 44.6 mg per 100 ml.
Since normal ranges for 1,25D levels are unclear, we analyzed the
tertiles of 1,25D levels according to its distribution in subjects
with eGFR460 ml min1 1.73 m2 (that is, those with relatively
preserved kidney function) and defined the lowest tertile as 1,25D
deficient (o30 pg ml1).
Statistical analyses
Baseline characteristics according to race were compared using two-
sample t-tests or Wilcoxon rank-sum tests for continuous variables;
Pearson w2-test was used for categorical variables. PTH, calcium,
phosphorus, 25D, and 1,25D were analyzed on a continuous scale and
according to the cut-off points defined above. Similarly, eGFR was
analyzed as a continuous variable and in groups according to CKD stage
(eGFR460 ml min1 1.73 m2, stage 2; 45–59, stage 3a; 30–44, stage 3b;
o30, stage 4). We tested for racial differences in mean or median levels
of PTH, calcium, phosphorus, 25D, and 1,25D in the overall population
and in groups according to CKD stage, and examined the overall and
stage-specific racial differences in the prevalence of 25D or 1,25D
deficiency, sHPT, hypocalcemia, and hyperphosphatemia using the
clinical cut-off points. To test for potential disparities in access to quality
medical care, we assessed whether there were differences by race in
utilization of angiotensin-converting enzyme inhibitors, b-blockers,
aspirin, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tors in Blacks vs non-Blacks overall and in those with a history of
coronary artery disease.
Multivariable regression analyses were performed to investigate
the association between Black race and levels of PTH, calcium,
phosphorus, alkaline phosphatase, 25D and 1,25D. Due to their
skewed distributions, PTH, alkaline phosphatase, and 1,25D were
log-transformed for multivariable analyses. Separate regression
analyses were performed for each of the outcome variables, and in
all models we adjusted for age, gender, diabetes, body mass index,
and eGFR. We performed additional analyses further adjusting the
PTH models for 25D, 1,25D, calcium, and phosphorus, to assess
whether Black race was associated with PTH independent of these
parameters. Similarly, we further adjusted the 1,25D models for
25D, its metabolic precursor, and adjusted the alkaline phosphatase
models for log PTH to determine whether racial differences in
alkaline phosphatase levels were independent of PTH. Logistic
regression was used to test whether the Black race was associated
with increased risk of sHPT, hypocalcemia, hyperphosphatemia, and
25D and 1,25D deficiency, adjusted for age, gender, diabetes, body
mass index, and eGFR. Two-sided P-values o0.05 were considered
statistically significant. All statistical analyses were performed using
SAS software, version 9.1 (SAS Institute, Cary, NC, USA).
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